Patent US3085892A successfully refreshed from Google Patents.
Patent US5767155A successfully refreshed from Google Patents.
US5767155A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Retinoid suppression of ventricular muscle cell hypertrophy
Assignee: University of California
•
Filing: 1996-07-22
•
Granted: 1998-06-16
•
Expires: 2016-07-22
Abstract
Abstract A method of suppressing ventricular muscle cell hypertrophy induced by an alpha 1-adrenergic agonist or endothelin, by providing an effective amount of a retinoic acid compound. Also provided are methods for identifying compounds which suppress ventricular muscle cell hypertrophy, compounds which inhibit the retinoic acid suppression of ventricular muscle cell hypertrophy, and therapeutic methods.
Inventors
- 👤 Kenneth R. Chien
- 👤 Ming Dong Zhou
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 02:23
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/94; G01N33/9453; A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/203; B; B01; B01D; B01D29/00; B01D29/11; B01D29/13; B01D29/15; B01D29/50; B01D29/52; B01D29/62; B01D29/66; B01D29/661; B01D2201/00; B01D2201/04; B01D2201/043; B01D2201/0446
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
52 words
A method of suppressing ventricular muscle cell hypertrophy comprising contacting ventricular muscle cells with an effective amount of a retinoic acid compound, said compound having the general formula ##STR2## or derivatives, and pharmaceutical salts thereof, said compound characterized by ability to bind a retinoic acid receptor and suppress ventricular muscle cell hypertrophy.
Claim 2
Independent Claim
52 words
A method of suppressing ventricular muscle cell hypertrophy comprising contacting ventricular muscle cells with an effective amount of a retinoic acid compound, said compound having the general formula ##STR2## or derivatives, and pharmaceutical salts thereof, said compound characterized by ability to bind a retinoic acid receptor and suppress ventricular muscle cell hypertrophy.
Claim 3
Dependent Claim
21 words
The method of claim 1 wherein said ventricular muscle cell hypertrophy is mediated by an α 1 -adrenergic agonist or endothelin.
Claim 4
Dependent Claim
31 words
The method of claim 1, wherein said retinoic acid compound is selected from the group consisting of all-trans retinoic acid, 9-cis retinoic acid, TTNPB, and 3-methyl-TTNPB, or a pharmaceutical salt thereof.
Claim 5
Dependent Claim
13 words
The method of claim 3, wherein said pharmaceutical salt is potassium or sodium.
Claim 6
Dependent Claim
13 words
The method of claim 1, wherein said ventricular muscle cells are human cells.
Claim 7
Dependent Claim
16 words
The method of claim 5, wherein said human cells are present in a living human heart.
References Cited (Backward Citations)
US5344644A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-15 | 2001-12-15 | 2002-06-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-15 | 2005-12-15 | 2006-06-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-15 | 2009-12-15 | 2010-06-16 | $7700.00 | Window Closed / Lapsed |